Novel Treatment Advances and Approaches in the Management of Advanced Breast Cancer: Expert Strategies for Individualized Treatment

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
AstraZeneca

Description:
Regardless of race or ethnicity, Breast Cancer is the most common cancer found in women. Athough death rates have been steadily decreasing over the past 20 years, patients in the later stages of disease, when distant metastases are present, are less likely to survive. Therefore, therapy in the advanced, metastatic setting focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment is also increasingly personalized, thanks to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents have been recently introduced or are in development for advanced breast cancer, including PARP inhibitors. With these options becoming available for the treatment of metastatic breast cancer, it is critical to provide medical professionals with updated clinical data and strategies.

Upon completion of this activity, participants will be able to:

  • Explore the mechanisms of action, efficacy and safety of new and emerging targeted therapies, including PARP inhibitors, for the treatment of advanced breast cancer

  • Outline the mechanistic rationale that underlies the application of PARP inhibition approaches for the management of breast cancer

  • Examine the impact of BRCA1/2 testing on clinical outcomes for patients with advanced breast cancer

  • Summarize strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies

  • Identify strategies that are being explored to maximize the efficacy of PARP inhibition in the treatment of patients with breast cancer

  • Assess the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into current advanced breast cancer management paradigm
     

Faculty: Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
University of Pittsburgh School of Medicine

Disclosure:

Dr. Brufsky serves as a consultant to Astrazeneca, Merck, and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue